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Koichi Goto,* Hironobu Ohmatsu,* Nagahiro Saijo,* and Yutaka Nishiwaki*
Introduction: Concurrent chemoradiotherapy with full doses of cis-
platin-based chemotherapy is standard treatment for inoperable stage III
non-small cell lung cancer (NSCLC). Although many platinum-based
two drug combinations with third-generation agents are difficult to
combine fully with thoracic radiotherapy (TRT), a phase I study
reported a full dose of cisplatin (CDDP) plus 80% dose of vinorelbine
(VNR) was successfully combined with concurrent TRT.
Methods: Between October 2000 and October 2004, 73 patients
with inoperable stage III NSCLC treated with CDDP, VNR, and
concurrent TRT were retrospectively analyzed. Patients were treated
with CDDP 80 mg/m2 on day 1 and VNR 20 mg/m2 on days 1 and
8 every 4 weeks. Radiotherapy was administered concurrently in
cycle 1. The total radiation dose was 60 Gy in 30 fractions. Common
Terminology Criteria for Adverse Events version 3.0 were used to
assess treatment-related adverse events.
Results: Median age was 63 years (40–78). Twenty-nine patients
had adenocarcinoma, 63 were male, 47 ECOG PS 1, and 47 stage
IIIB. Median chemotherapy cycle was 2.0. Objective response rate
was 93% and median survival time was 21 months. Three-year
overall survival rate was 33%. Infield control rate was 71%. The
most common grade 3 or 4 adverse event was leukocytopenia (67%).
Only 3 patients (4%) experienced grade 3 esophagitis. One patient
died of radiation pneumonitis 87 days after completion of chemo-
radiotherapy.
Conclusions: Concurrent chemoradiotherapy with CDDP and VNR
was highly active and well-tolerated. This regimen could be used as
a control arm in future trial for stage III NSCLC.
Key Words: Concurrent chemoradiotherapy, Non-small cell lung
cancer, Cisplatin, Vinorelbine.
(J Thorac Oncol. 2008;3: 617–622)
Lung cancer is the leading cause of cancer-related deathsthroughout the world, including Japan.1 Stage III inoper-
able non-small cell lung cancer (NSCLC) constitutes approx-
imately 30% of all newly diagnosed cases of NSCLC.2
Historically, patients with stage III NSCLC were treated with
thoracic radiotherapy (TRT) alone. Nevertheless, the survival of
patients treated with TRT alone was poor, with a 5-year survival
rate of approximately 5%.3 As the treatment option of chemo-
radiotherapy (CRT) has developed, the survival of patients with
stage III NSCLC has improved, with 3-year survival of approx-
imately 15–20% and median survival time (MST) of 15–20
months.4,5 Several randomized trials have demonstrated that
concurrent CRT using full dose of cisplatin-based chemotherapy
improves long-term survival compared with sequential CRT.6–9
Although two-drug combinations with cisplatin (CDDP) and
third-generation agents including vinorelbine (VNR), docetaxel,
paclitaxel, gemcitabine, and irinotecan are standard chemother-
apy regimens for stage IV NSCLC10–12, it is difficult to deliver
full doses of these regimens and concurrent TRT because of
excessive toxicity.
Recently a phase I trial of CDDP, VNR, and concurrent
RT was reported.13 The recommended doses were CDDP 80
mg/m2 on day 1 and VNR 20 mg/m2 on days 1 and 8. Although
this was a phase I study, an encouraging survival rate of 50% at
3 years was reported. On the basis of this result, we have treated
inoperable stage III NSCLC patients with CDDP, VNR, and
concurrent RT in clinical practice at the National Cancer Center
Hospital East, Japan. Herein is our review of the efficacy and
tolerability of CRT with CDDP and VNR.
MATERIALS AND METHODS
The objective of this retrospective analysis was to
evaluate the efficacy and tolerability of concurrent CRT using
CDDP and VNR.
Patient Selection
We reviewed consecutive 106 inoperable stage III
NSCLC patients who were treated with CDDP, VNR, and
concurrent TRT at the National Cancer Center Hospital East,
Japan, between October 2000 and October 2004. Clinically
apparent or histologically/cytologically proven N2/N3 dis-
ease or T4 otherwise pulmonary metastasis in the same lobe
was considered “inoperable.” Chest CT, abdominal CT/ultra-
sonography, bone scintigram or FDG-PET, and brain MRI/CT
were performed in all patients. In general, lymph nodes that
were larger than 1.0 cm in minor axis were considered as
metastatic. Lymph nodes that were involved in multiple
stations were considered ‘clinically apparent N2/3.’ To con-
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firm N2 disease, which was detected in chest CT and con-
sidered ‘not apparent,’ FDG-PET and/or mediastinoscopy
was performed. FDG-PET (or PET/CT) was performed in 18
patients. Mediastinoscopy was performed in ten patients. In
addition, there were 5 histologically/cytologically confirmed
N3 (supraclavicular lymph nodes) diseases. Thirty-three pa-
tients were excluded because they participated in a clinical
trial that evaluated CDDP plus VNR followed by docetaxel,14
therefore 73 patients were evaluated in the present analysis.
Data of survival, recurrence, and treatments after failure were
obtained from medical records. All patients were evaluated at
weekly case conference in which radiation oncologists and
medical oncologists who had special expertise in thoracic
oncology made treatment decisions. Inclusion criteria for
CRT in our institution were generally as follows; white blood
cell count 3.0  109/liter, platelet count 10.0  109/liter,
serum creatinine 1.5 mg/dl, total bilirubin 1.5 mg/dl, and
transaminase less that twice the upper limit of the normal
value. Exclusion criteria were pulmonary fibrosis identified
by a chest x-ray, malignant pleural or pericardial effusion,
and a concomitant serious illness, such as uncontrolled an-
gina pectoris, myocardial infarction in the previous 3 months,
heart failure, uncontrolled diabetes mellitus, severe respira-
tory failure and uncontrolled hypertension. All patients gave
informed consent before CRT.
Chemotherapy
Chemotherapy consisted of CDDP (80 mg/m2 on day 1)
and VNR (20 mg/m2 days on 1 and 8). Treatment cycles were
repeated every 4 weeks with a maximum of 3 cycles admin-
istered. Cisplatin and VNR were administered by intravenous
infusion. All patients received prophylactic antiemetic ther-
apy consisting of 5-HT3 antagonist, metoclopramide, and
dexamethasone. If a patient experienced excessive adverse
events, dose reduction of both drugs was implemented during
the subsequent treatment cycle. When leukocyte or platelet
counts were inappropriate, or if infection developed at day 8,
VNR was withheld.
Radiotherapy
TRT was administered concurrently in cycle 1. A
CT-scan based treatment planning was used in all patients.
The clinical target volume (CTV) for the primary tumor was
defined as the gross tumor volume plus 0.5–0.8 cm margin
taking account of subclinical extension. The CTV for meta-
static lymph nodes were the same as the gross tumor volume
for metastatic lymph nodes. Metastatic lymph nodes were
defined as the lymph nodes that were larger than 1.0 cm in
minor axis. Regional lymph nodes (mainly #3, #4, #7),
excluding the contralateral hilar and supraclavicular lymph
nodes, were included in the CTV for elective nodal irradia-
tion. The planning target volume for the primary tumor, the
metastatic lymph nodes, and regional lymph nodes was de-
termined as CTVs plus setup margin (0.5 cm) and internal
margins according to the respiratory motion on fluoroscopy
(circumferential 0.5 cm, cranial 0.5 cm, and caudal 1.0–1.5
cm). Lung heterogeneity corrections were not used, and the
doses were prescribed to the center of planning target vol-
ume. Principally, the initial radiation field was planned not to
exceed 50% of ipsilateral lung volume on chest radiograph,
or since August 2003, V20 of the normal lung (the percent
volume of normal lung receiving 20 Gy or more) was planned
not to exceed 35%. The total radiotherapy dose was 60 Gy in
30 fractions (5 fractions per week) delivered over 6 weeks.
Radiation therapy was delivered with megavoltage equipment
(6 mV) using parallel opposed fields up to 40 Gy in 20
fractions including primary tumor, the metastatic lymph
nodes, and the regional lymph nodes. A booster dose of 20
Gy in 10 fractions was given to the primary tumor and the
metastatic lymph nodes according to the CT obtained after
initial 40 Gy radiation, using opposed oblique fields to avoid
excessive dose to the spinal cord.
Evaluation of Efficacy and Adverse Events
Overall survival was defined as time from start of
chemoradiotherapy to death of any cause. Progression-free
survival was defined as time from start of chemoradiotherapy
to the first documented disease progression or death. Disease
progression was subdivided into infield relapse or not. Chest
CT was used to asses if the relapse was within the initial
radiation field. Response Evaluation Criteria in Solid Tumor
criteria were used to assess the best tumor response. Chest CT
was reviewed independently by a radiologist. The response
rate was calculated as the total percentage of patients with a
complete or partial response. In principle, the chest CT was
taken 2 and 4 months after starting chemoradiotherapy and as
needed to evaluate the response and toxicity. Treatment-
related adverse events were evaluated using the Common
Terminology Criteria for Adverse Events Version 3.0. Late
toxicities were scored according to the European Organization
for Research and Treatment of Cancer/Radiation Therapy On-
cology Group late radiation morbidity scoring scheme.
Statistical Analyses
Multivariate analyses were performed using Cox re-
gression models. Expected prognostic factors included age
(70 years versus 70), gender (male versus female), East-
ern Cooperative Oncology Group (ECOG) performance sta-
tus (0 versus 1), clinical stage (IIIA versus IIIB), smoking
history (30 pack-year versus 30), histology (adenocarci-
noma versus others), tumor size (5 cm versus5 cm), stage
(IIIA versus IIIB), and weight loss (5% versus 5%).
Kaplan–Meier methods were used to graphically describe the
distribution of survival. All statistical analyses were per-
formed using SPSS II for Windows version 11.0.1J.
RESULTS
Patients’ characteristics are shown in Table 1. Median
number of chemotherapy cycles were 2.0 (mean 2.4, ranges
1–3). Dose reduction of chemotherapy was implemented in
11 patients mainly due to grade 4 leukocytopenia. Two
patients did not receive full dose of radiotherapy. In one
patient, radiotherapy was discontinued at the dose of 40 Gy
because the tumor was located nearby the spinal cord, and in
the other patient because of declined PS.
All 73 patients were assessable for survival, time to
progression, response rate, and adverse events. No patient
achieved complete response. Partial response, stable disease,
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and progressive disease were observed in 68, 5, and 0 patient,
respectively (Table 2). The response rate was 93.2% (95%
confidence interval; 87.2–99.1%). Median progression free
survival time was 12 months and median overall survival
time was 21 months with median follow-up of 35 months
(ranges 23.7–61.2). Two- and 3-year survival rate was 44 and
33%, respectively. The Kaplan–Meier plots of overall sur-
vival are shown in Figure 1; Figure 2 shows progression-free
survival. Multivariate analysis showed that no variables sig-
nificantly affected the overall survival (Table 3).
There were 46 disease relapses and 50 deaths. Infield
relapses were observed in 21 patients (11 without and 10 with
relapse outside of the radiation fields); therefore infield con-
trol rate was 71%. Distant metastases were the first sites of
the failure in 35 patients; brain (n  16), bone (n  10),
adrenal gland (n  5), liver (n  3), and lung (n  16).
Seventeen patients received docetaxel and 12 received ge-
fitinib as second line treatment. None responded to docetaxel
and two patients (16%) responded to gefitinib (and 1 achieved
partial response).
FIGURE 1. Overall survival of patients treated with CDDP 
VNR  concurrent RT. CDDP, cisplatin; VNR, vinorelbine; RT,
radiotherapy; MST, median survival time; 3-year survival,
survival rate at 3 years.
FIGURE 2. Progression-free survival of patients treated
with CDDP  VNR  concurrent RT. CDDP, cisplatin;
VNR, vinorelbine; RT, radiotherapy; MPFST, median pro-
gression-free survival time; 3-year survival, progression-
free survival rate at 3 years.
TABLE 1. Patient Characteristics
Patients (n  73)
No. %
Age
Median (range) (yr) 63 (40–78)
70 yr 48 66
70 yr 25 34
Gender
Female 10 14
Male 63 86
Histological diagnosis
Adenocarcinoma 29 40
Squamous cell carcinoma 28 38
Others 16 22
Tumor size
Median (range) (cm) 5.4 (1.5–12.0)
5 cm 33 45
5 cm 40 55
ECOG performance status
0 26 36
1 47 64
Smoking history
Never smoker 5 7
30 pack-yr 11 15
30 pack-yr 57 78
Stage
IIIA 26 36
T3N1 3 4
N2 23 32
IIIB 47 64
T4a 40 55
N3 12 16
Body weight loss (recent 6 mo)
5% 58 79
5% 15 21
a Six were T4N0, 3 were T4N1, and 5 were T4N3.
TABLE 2. Overall Objective Response
Number %
Number of patients evaluated 73
Complete response (CR) 0 0
Partial response (PR) 68 93.2
Stable disease (SD) 5 7.8
Progressive disease (PD) 0 0
Response rate (95% CI) 93.2 (87.2–99.1)%
CI, confidence interval.
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The incidence of treatment-related adverse events is
listed in Table 4. The most common grade 3 or 4 adverse
event was leukocytopenia (67%). Grade 3 or 4 neutropenia
was observed in 38 patients (52%). Grade 3 or 4 thrombo-
cytopenia was not observed; grade 3 or 4 anemia occurred in
17 patients (23%). Only 3 patients (4%) experienced grade 3
esophagitis related to radiotherapy. Five patients (7%) devel-
oped grade 3 or 4 pneumonitis and one of them died of
respiratory failure 87 days after completion of chemoradio-
therapy. The autopsy revealed diffuse alveolar damage com-
patible with radiation pneumonitis and fibrosis. None of the 5
patients with grade 3 or 4 pneumonitis received second line
chemotherapy. Another patient of them developed grade 3
pulmonary fibrosis, but no other severe late radiation mor-
bidity was observed.
DISCUSSION
Chemoradiotherapy is standard treatment for patients
with inoperable stage III NSCLC. Several trials indicate that
concurrent CRT improves long-term survival compared with
sequential CRT.6–9 Nevertheless, the optimal regimen and
dose of chemotherapy has not been determined yet. The
efficacy of chemoradiotherapy with CDDP and vinca alka-
loids or etoposide has been reported, and CDDP plus vin-
desine with or without mitomycin has been one of the
standard chemotherapy regimens.6,15–17
VNR is a newer semi-synthetic vinca alkaloid and more
active than vindesine against metastatic NSCLC.18 Zatloukal
et al.8 reported the efficacy of CRT with CDDP and VNR in
a randomized phase II trial, which randomized concurrent
CRT or sequential. Concurrent arm was favored in overall
survival (MST was 16.6 months in the concurrent arm and
12.9 months in the sequential arm). Vokes et al.19 also
reported the efficacy of CRT with CDDP and VNR in
randomized phase II trial, which randomized 3 CDDP-based
combination chemotherapies with third-generation agents. In
this series, MST of all patients were 17 months and 3 year
survival of VNR arm was 23%. With these results, concurrent
CRT with CDDP and VNR could be considered one of the
new standard regimens for stage III NSCLC, although the
employed VNR doses in each phase II study were 12.5 mg/m2
and 15 mg/m2. Standard doses of CDDP plus VNR for
metastatic NSCLC are 80 mg/m2 of CDDP and 25 mg/m2 of
VNR. The doses of 20 mg/m2, employed in the present study,
are close to the standard. Moreover, 20 mg/m2 of VNR alone
has reported to be active in advanced NSCLC, with response
rate of 21.7%.20
Results of the present study were encouraging, demon-
strating MST of 21 months and a 3-year survival rate of 33%.
Our study confirmed clinical usefulness of combination che-
motherapy with CDDP, VNR, and simultaneous TRT.
The most common treatment-related adverse events were
hematological (grade 3 or 4 leukocytopenia in 67%, neutropenia
in 52%, and anemia in 23%), and these were well tolerated.
There were 5 patients (7%) who developed grade 3 or more
pneumonitis and only one patient (2%) died of radiation pneu-
monitis. The incidence and mortality of radiation pneumonitis
was comparable with other reports.6,8,9,19,21–24 Recently we
have evaluated dose volume histogram and plan V20 not to
exceed 35% in CRT, which may contribute to reducing
severe radiation pneumonitis.
Low incidence of severe radiation-related esophagitis in
our study deserves special mention. In the present study grade 3
esophagitis was developed in only 3 patients (4%), which is
lower than other studies of concurrent chemoradiotherapy
where radiation-related esophagitis was reported to be in the
range of 12–46%,21–23 with the exception of one study using
CDDP, vindesine (VDS), and mitomycin.6 In this report, the
incidence of grade 3 or more radiation-related esophagitis
was only 3%. The cause of this difference is still unknown;
however, low incidence of esophagitis may correlate with the
use of vinca alkaloids and Japanese studies. Further exami-
nation is warranted. We believe that highly conformal ther-
apy could reduce the rate of esophagitis. Overall, chemora-
diotherapy with CDDP and VNR were well tolerated.
Although the collection of toxicity data retrospectively
is of concern, most patients were treated as inpatient through-
TABLE 3. Prognostic Factors Treated with CDDP  VNR 
Concurrent TRT (n  73)
Parameter Hazard Ratio 95% CI p
Age (70 yr vs. 70) 1.787 0.941–3.394 0.076
Gender (male vs. female) 1.364 0.490–3.799 0.553
PS (0 vs. 1) 0.818 0.435–1.537 0.533
Clinical Stage (IIIA vs. IIIB) 1.109 0.588–2.093 0.749
Smoking (30 pack-yr vs. 30) 0.698 0.321–1.519 0.365
Tumor size ( 5 cm vs. 5) 0.862 0.473–1.569 0.626
Histology (Ad vs. others) 1.565 0.766–3.198 0.219
Body weight loss (5% vs. 5) 1.567 0.786–3.125 0.202
CI, confidence interval; Ad, adenocarcinoma.
TABLE 4. Grade 3 or 4 Treatment-Related Adverse Events
(NCI-CTC vs. 3.0, n  73)
Adverse Event
Grade
3 (%)
Grade
4 (%)
Leukocytes 32 36
Neutrophiles/granulocytes 25 27
Hemoglobin 22 1
Platelets 1 0
Febrile neutropenia 14 0
Infection with grade 3 or 4 neutropenia 1 0
Infection without neutropenia 10 0
Pneumonitis/pulmonary infiltrates 5 1a
Radiation esophagitis 4 0
Radiation dermatitis 0 0
Anorexia 16 0
Nausea 8 0
Vomiting 5 0
Diarrhea 1 0
Creatinine 0 0
Supraventricular arrhythmia (atrial fibrillation) 1 0
a One patient died from radiation pneumonitis 87 d after completion of chemora-
diotherapy.
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out the treatment course, and toxicity data were recorded on
medical records in detail. It should be confirmed by a pro-
spective study.
Taxanes are also investigated widely in patient with
unresectable stage III NSCLC. Weekly administration with
carboplatin (CBDCA) plus paclitaxel (PTX) and concurrent
RT was reported in multiinstitutional phase II study. Re-
ported MST was promising, with 20.5 months.25 Neverthe-
less, recently reported phase III trial compared induction
chemotherapy plus CRT with CRT alone, which employed
weekly CBDCA and PTX, showed disappointing results, with
MST of 14 months and 12 months, respectively.26 The
authors concluded that the routine use of weekly CBDCA and
PTX with simultaneous TRT should be re-examined. Che-
motherapy with docetaxel (DOC) plus CDDP and concurrent
TRT was also reported in a phase I/II study.21 The result was
promising, with MST of 23 months, and phase III trial
comparing DOC and CDDP to CDDP, VDS, and mitomycin
is currently underway.
Local recurrence was observed in 21 patients (29%),
and the brain was also a major site of treatment failure (16
patients, 22%). These results are comparable to the litera-
ture.21 On the basis of these observations, other radiation
approaches such as hyperfractionated radiotherapy or high-
dose thoracic radiation to improve local control should be
considered.27–31 Moreover, whether prophylactic cranial irra-
diation reduces the incidence of brain metastases should be
confirmed.
Advanced age did not correlate with worse prognosis
and it is compatible with literature.32 Gender, tumor size,
body weight loss, smoking status did not significantly corre-
late with shorter overall survival, and it may be due to the
small sample size of our study.
We excluded 33 patients who participated in the trial
evaluated consolidation docetaxel after concurrent CRT
with CDDP and VNR.14 Sekine and colleagues reported
that majority of patients could not continue with consoli-
dation docetaxel after concurrent CRT with CDDP and
VNR because of pulmonary toxicity. Although consolida-
tion therapy using docetaxel seems to be highly effective
in SWOG phase II study,33 randomized phase III trial
failed to demonstrate that addition of consolidation do-
cetaxel improves survival.34
Two patients did not receive full dose of radiotherapy.
Nevertheless, these two patients were treated initially with
curative intent. Therefore we included these two patients in
this analysis. Moreover, exclusion of these two patients did
not alter the results (data not shown).
In conclusion, chemoradiotherapy with CDDP and
VNR was promising and well tolerated. This regimen could
be used as a control arm in future trial for stage III NSCLC.
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